O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS
M.P. Manns, Stephanie Noviello(Novartis (United States)), Guido Gerken, Marc Bourlière(Universität Hamburg), Everson Gt, Justin Kopit(Gdańsk Medical University), Jeong Heo(National Cancer Center), Stuart C. Gordon(United States Department of Veterans Affairs), Emma Hughes(National Institutes of Health), Patricia Méndez, Misti Linaberry(Bristol-Myers Squibb (United States)), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), William Sievert(Monash Health), D. Thabut, Ira M. Jacobson(Cornell University), Sophie Métivier, Y.-J. Lee, Fiona McPhee(Bristol-Myers Squibb (United States)), Boris Yoffe(Baylor College of Medicine), T.-T. Chang, C.‐J. Chu, S. Pol(Hôpital Cochin), W.J. Towner, J.-P. Bronowicki, Patrick Marcellin(Inserm)
Cited by 20
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
|New England Journal of Medicine|2004|1.1k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k